Grunenthal

Private

#Pain Management #Oncology #Inflammation

Family-owned German pharmaceutical company focused on pain management and adjacent therapies; in September 2026 it agreed to acquire Bayer's oncology drug Stivarga for up to 375 million euros.

Company Info

Sector:Pharmaceuticals

Headquarters:Aachen, Germany

Founded:1946

Website:www.grunenthal.com

Upcoming Milestones & Key Dates

2026

M&A

Close of Stivarga acquisition from Bayer (up to 375M euros)

Clinical Development Pipeline

Stivarga (regorafenib)

Target: Multi-kinase inhibitor

Metastatic colorectal cancer and gastrointestinal stromal tumors

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

Business & Strategy•Sep 21, 2026•Fierce Pharma

Bayer sells cancer drug Stivarga to Grunenthal for up to $431M ↗

Bayer is offloading its aging cancer drug Stivarga to German compatriot Grunenthal for up to 375 million euros ($431M) as a potential new competitor from Exelixis nears an FDA decision; Stivarga's patents run to 2029 in the EU and 2030 in the U.S.

Leadership Team

Gabriel Baertschi

Chief Executive Officer

Careers & Job Openings

See all open roles

Careers

Various

Apply Now →